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The package tour holiday industry, the 
expansion of international trade and the 
speed of travel are all playing a major role in 
the problem of 'imported diseases' , espe­
cially as tourists are becoming increasingly 
adventurous and travelling to more remote 
and exotic places year by year. 
Of all the travel-associated diseases malig­
nant tertian malaria due to Plasmodium fal­
ciparum is the most important. There is no 
other ' tropical' illness that changes so dram­
atically from a relatively benign infection to 
a catastrophic and fatal one in the space of a 
few days. In 1987 in Britain, 7 deaths due to 
P.falciparum were recorded and up to July 
1988 already 3 deaths had occurred. All the 
fatalities were due either to misdiagnosis or 
delayed treatment. Unless practitioners 
become aware of this problem, however rare 
in their experience it may be, unnecessary 
deaths will continue to occur. The simple 
routine habit of eliciting a recent geographi­
cal history has yet to become accepted good 
medical practice in many non-endemic 
malarious areas of the world. Unde Venis 
viator et quo vadis? ' 2 
'Airport' malaria is now well documented:'. 
It occurs in persons working or living near 
airports, recipients of flights from Africa in 
particular. 
Chloroquine and indeed multidrug resist­
ant malaria is one of the most worrying 
developments of recent years, especially as 
it has now established a firm foot-hold in 
Africa South of the Sahara, in several coun­
tries where P.falciparum transmission is 
hyperendemic, and basic health services 
relatively poorly developed.' 
The chemotherapy and management of 
malaria have recently been reviewed.' h 7 
The approach is a two-pronged one - chemo­
therapeutic and supportive - both are 
equally important, and common errors 
should be avoided. 
a. COMMON ERRORS 
IN THE MANAGEMENT 
OF SEVERE P. 
FALCIPARUM 
MALARIA. 
1) 	 Failure to take a travel history 
2) 	 Assumption that chemoprophylaxis is 
completely protective 
3) 	 Failure to consider 'induced' malaria ­
i.e. 	 blood transfusion and contami­
nated needles 
4) Misjudgment of severity 
5) Poor standard oflaboratory diagnosis 
6) Missed hypoglycaemia 
7) Errors of fluid and electrolyte balance 
8) Inadequate nursing care 
9) Failure to control convulsions 
10) Failure to recognise and treat severe 
anaemIa 
11) 	 Use of potentially dangerous ancil­
liary therapies, e.g. corticosteroids, 
heparin 
12) 	 Delay in starting haemo or peritoneal 
dialysis 
b. THE 
MANAGEMENT OF 
THE SEVERE 
MANIFESTATIONS OF 
FALCIPARUM 
MALARIA IS GIVEN IN 
TABLE 1. 
Table I. Severe complications of falciparum malaria and their management 
(After WHO 1989 - in press) 
Complication 
1. Coma (cerebral malaria) 
2. 	 Hyperpyrexia 
3. Convulsions 
4. 	 Severe anaemia (packed cell 
volume less than 20%) 
5. 	 Acute pulmonary oedema 
6. 	Acute renal failure 
7. 	 Spontaneous bleeding and 
coagulopathy 
8. 	 Metabolic acidosis 
9. 	Hypoglycaemia 
10. 	Gram-negative septicaemia 
("Algid malaria") 
11. Aspiration pneumonia 
12. Hyperparasitaemia (> 20%) 
Management* 

Maintain airway, nurse on side, exclude other 

treatable causes of coma(e.g., bacterial 

meningitis). Avoid harmful adjuvant treatments 

such as corticosteroids, heparin and adrenaline. 

Tepid sponging, fanning, dipyrone injection. 

Maintain airway, diazepam or paraldehyde 

injection (Prevent with phenobarbital 

intramusculary - 3.5 mg/kg one single dose on 

admission) 

Transfuse fresh whole blood or packed cells 

Prop up at 45°, give oxygen, venesect 250 ml of 

blood into donor bag, give diuretic, stop 

intravenous fluids. 

Exclude dehydration: strict fluid balance, 

peritoneal dialysis (haemodialysis if available). 

Transfuse fresh whole blood, vitamin K 

injection. 

Exclude or treat hypoglycaemia, hypovolaemia 

and Gram-negative septicaemia. Give oxygen. 

Give 50% dextrose injection followed by 5% to 

lO'lf, dextrose infusion. 

Give parenteral antimicrobials, correct haemo­

dynamic disturbances. 

Give parenteral antimicrobials, change position, 

physiotherapy, give oxygen. 

Exchange transfuse 4 or more units of fresh 

whole blood 

It is assumed that quinine or chloroquine infusion will have been started in all cases. 
L-________________________________________________________________________-J!~ 
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~ C. 	 ERRORS OF 
ANTIMALARIAL 
CHEMOTHERAPY 
1) 	 Delay in starting treatment 
2) 	 Incorrect dosage 
3) 	 Inadequate dosage 
4) 	 Inappropriate route of administration 
e.g. "bolus" injection intravenously 
5) Failure to control the rate of intrave­
nous infusions 
-
6) Failure to switch patients from paren­
teral to oral therapy as soon as they can 
swallow 
d.THE 
CHEMOTHERAPY OF 
P. 	FALCIPARUM 
MALARIA8 
Quinine is the treatment of choice:­
(i) 	 In areas of the world where chloro­
quine resistance is established or 
suspected 
(ii) 	 In cases of doubt as to the origin of the 
malaria or the existence of resistance 
(iii) 	 Where malaria has been acquired des­
pite chloroquine prophylaxis. 
The drug is given orally in uncomplicated 
cases or by slow intravenous infusion in 
severe malaria. 
Chloroquine is an effective treatment if the 
parasite is fully sensitive to the drug. Unfor­
tunately, in many of the malarious coun­
tries this is no longer the case. However, if 
the cinchonal alkaloids - quinine or quini­
dine - are not available, chloroquine can be 
life-saving since it will reduce parasitaemia 
if resistance is at the RI or RII level. 
Antimalarial chemotherapy is summarised 
in Table n. 
Table n. Antimalarial drugs for the 
Uncomplicated infections (able to swallow 
tablets) 
Chloroquine-sensitive areas (and areas of 
Plasmodium vivax, Plasmodium ovale l and 
Plasmodium malariae) 
Chloroquine base, 600 mg immediately, 
followed by chloroquine base, 300 mg 8 
hours later and daily on days 2, 3 and 4 
Chloroquine resistant areas 
(1) 	 Quinine 600 mg (salt) 8 hourly for 7 
days plus single dose of Fansidar 3 
tablets, i.e. (Sulfadoxine 1500 mg + 
pyrimethamine 75 mg)" 
OR 
(2) 	 Quinine, 600 mg (salt) 8 hourly for 7 
days plus tetracycline", 250 mg 6 
hourly for 7 days 
OR 
(3) 	 Mefloquine, 1000 mg (salt) single 
doseL 
NOTES 
1. 	 For P.vivax and P.ovale infections add 
primaquine, 15 mg daily for 14-21 days 
2. 	 Sulpha-antifolate resistance is wides­
pread, therefore check current pattern 
of drug resistance. 
3. 	 Tetracycline should not be given to chil­
dren under 8 years or pregnant women. 
4. 	 Quinidine can be substituted for qui­
nine. ECG changes (prolongation of the 
QT interval) and hypotension will 
occur, so these effects should be 
monitored. 
5. 	 A loading dose should not be used if 
quinine has been given in the previous 
12 hours. 
As soon as the patient can swallow tablets 
quinine 600 mg (salt) 8 hourly for 7 days 
should be substituted or preferably an oral 
dose of 1000 mg (salt) ofmefloquine is given 
either as a single dose or in two divided 
doses 500 mg each dose at an interval of 6 
hours. The latter regimen may reduce the 
possibility of vomiting. 
CHEMOPROPHYLAXIS 
Several basic points must be emphasized ­
1. It must never be assumed that chemo­
prophylaxis, even when taken regularly, 
will al ways protect against malaria - protec­
tion is relative. Thus, every non-immune 
person residing temporarily or for longer 
periods in a malarious area must be warned 
that, if he feels ill, malaria must still be 
excluded as a possible diagnosis. This is par­
ticularly relevant because of the spread of 
resistance to many antimalarial drugs and 
the absence of accurate and comprehensive 
TIlaps of the distribution of resistance to the 
antimaliarials in current use. Evidence of 
resistance . based on 'clinical' experience 
often without concomitant and competent 
microscopic diagnosis ofmalaria has aggra­
vated an already complex situation. 
2. 	 Accept with the greatest scepticism that 
treatment of malaria in adults 
Complicated infections 
Chloroquine-sensitive areas 
Chloroquine 5 mg base/kg i.v. infusion 
given over 4-6 hours, every 12 hours 
(total dose 25mg/ kg) 
Chloroquine· resistant areas 
Quinine dihydrochloride' 20 mg salt/kg 
loading dose-' i. v. infusio n gi ven 0 ver 4 
hours, followed by 10 mg/kgi. v. infusion 
given over 4 hours every 8 hours (intra­
muscular injection into the lateral thigh 
can be used if intravenous infusion is 
impossible). 
any potentially malarious area is free from 
risk. Anecdotes that in West Africa, for 
example, cities are malaria free are quite 
inaccurate. 
3. Malaria can be acquired at relatively 
short stops on a journey, for example, while 
refuelling the aeroplane. 
4. It is important to have adequate blood 
levels of antimalarials by the time a person 
is at risk. This can be achieved by taking a 
dose the day before departure. Despite this, 
it is considered wise to begin antimalarials 1 
week before travelling in order to get used to 
the habit and to detect rare cases of 
idiosyncrasy. 
5. Antimalarial chemoprophylaxis must 
be continued for 4 weeks after returning 
from an endemic area and the need to conti­
nue must be stressed. 
6. It is important to remember that PIal­
ciparum can recrudesce for 1 year and 
P.vivax up to 5 years. Any fever occurring 
during this period should be suspected to be 
malaria until the contrary is proved, irres­
pective of whether the person has been on 
chemoprophylaxis or not. 
7. Special risk groups, such as pregnant 
women, infants, over 70 year old, immuno­
deficient patients or those on other long­
term medication, should seek up-to-date 
advice on the appropriate prophylaxis from 
specialized centres in their respective 
countries. 
The regiments for chemoprophyalaxis cur­
rently recommended in Britain are given in 
Table Ill. 
Table IlL Chemoprophylaxis 
regimens for short-term « 4 weeks) 
travellers 
Countries where Plasmodium falciparum is 
sensitive to chloroquine 
(North Africa!, the Middle Eastl, and Cen­

tral America) 

Chloroquine, 300 mg base (2 tablets) once 

weekly 

OR 

Proguanil hydrochloride, 200 mg daily 

Countries where Plasmodium falciparum is 
resistant to chloroquine 
(all countries except those above and the 
'hard-core; countries below) 
Chloroquine, 300 mg base (2 tablets) once 
weekly (for P.vivax infections) plus progua­
nil hydrochloride, 200 mg daily 
'Hard-core' Plasmodium falciparum multi­
drug resistant countries 
(Thailand, Laos, Kampuchean border 
areas, South Vietnam, Papua New Guinea, 
rural areas of the Philippines) 
Pyrimethamine plus dapsone (Maloprim), 
one tablet weekly plus chloroquine, 300 mg 
base (2 tablets) weekly 
OR 
Mefloquine (if available), 250 mg once 
weekly 
~____________________~~~::~~i7~I~ 
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NOTE 

1 Malaria transmission in North Africa 
and the Middle East is low, focal, seasonal 
and predominantly due to P.uiuax. Chemo­
prophylaxis is not essential providing 
prompt treatment is sought in the event of 
an illness occurring 10 days after exposure. 
Long-term travellers and non-immune resi­
dents of malarious areas should follow the 
same regimen as 'short-term' travellers 
unless advised otherwise by the competent 
authorities in the countries concerned. 
SELF TREATMENT 
Under certain conditions self-treatment is 
not only permissible, but justified. It is man­
datory, however, that this practice should 
not be abused. Standby antimalarial agents 
for 'self-treatment' are pyrimethamine plus 
sulfadoxine (Fansidar), or in very special 
circumstances mefloquine (if available). 
Treatment for malaria should not be consi­
dered until at least 10 days have elapsed 
after entering an endemic area (the incuba­
tion period of Pfalciparum malaria is usu­
ally 10-12 days). 
PERSONAL 

PROTECTION 

Personal protection has become as impor­
tant as taking antimalarial drugs. Some 
basic measures for reduction of exposure to 
mosquito bites are: 
Use of mosquito nets 
Screening of houses 
Use of repellants 
Spraying of rooms before retiring to bed 
Use of mosquito coils 
Adequate clothing (e.g . long sleeves and 
trousers in the evenings) 
SUMMARY 
A review of the modern management and 
chemotherapy of malaria, the most impor­
tant parasitic disease in the world. 
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